ENANTA PHARMACEUTICALS INC — Director's Dealing 2018

Sep 21, 2018

SEC Form 4/A — Form 4/A

Issuer: ENANTA PHARMACEUTICALS INC (ENTA)
CIK: 0001177648
Period of Report: 2018-07-18

Reporting Person: Adda Nathalie (Sr. VP & Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-07-18	Common Stock	S	1185	$123.7155	Disposed	5370	Direct
2018-07-18	Common Stock	S	445	$124.2008	Disposed	4925	Direct
2018-07-18	Common Stock	S	1621	$125.6029	Disposed	3304	Direct
2018-07-18	Common Stock	S	904	$126.3953	Disposed	2400	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018.

F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $122.925 to $123.87, inclusive.

F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $123.95 to $124.48, inclusive.

F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $125.09 to $126.07, inclusive.

F5: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $126.12 to $126.90, inclusive.

F6: The Form 4 filed by the reporting person on July 19, 2018 is being amended to correct: (i) a scrivener's error with regard to the number of shares reported as disposed in column 4 and (ii) the corresponding amount of securities beneficially owned following reported transactions in column 5. The subsequent Form 4 filed by the reporting person on August 21, 2018 does not reflect the correction made in this amendment to the amount of securities beneficially owned following reported transactions.